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
Asyou’reallaware,interestinthecervicalVEMPswasrevived
byColebatchandHalmagyiintheearly1990s.

Stimulationofthesacculewithaloudacousticstimuluscauses
atransientinhibitionoftheipsilateralsternocleidomastoid
muscleviathispathwaycreatingawaveformthatlookslikethis.
It’sanincrediblyusefulobjectivetestofotolithfunctionthat
hasfoundmanyuses.


 
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Ménière’s Disease and cVEMPs
 Cervical VEMPs (cVEMPs) have been used as part of the test battery for 
Ménière’s disease (Colebatch et al., 1994; Bath et al., 1998; Rauch et 
al., 2004b), primarily showing amplitude and threshold differences 
compared to controls.
 cVEMP abnormalities seen more than half of all participants with 
Ménière’s disease (Ribeiro et al. 2005 - 50%, de Waele et al. 1999 -
54%, and Kuo et al. 2005 - 67%).
 Amplitude changes found by Rauch et al. (2004b), Rauch et al. (2004b), 
Ohki, Matsuzaski, Sugasawa, & Murofushi, (2002), Akkuzu et al. (2006) 
and Murofushi et al. (2001), Chen & Young (2006).
 Threshold changes found by Lin, Timmer, Oriel, Zhou, Guinan, Kujawa, 
Herrmann, Merchant, & Rauch (2006) and Rauch et al. (2004b).
 However, a lack of statistically-significant differences in threshold reported by 
Osei-Lah et al. (2008).  

Notsurprisingly,it’sbeeninvestigatedbymanyresearchersas
partofatestbatteryapproachforthediagnosisofMénière’s
disease.

ThemainfindingshavebeenabnormalitiesinthecVEMP
waveformin50to67%ofparticipantswithMénière’sdisease
mainlyinthepeakamplitudes.

ChangesinthethresholdoftheresponseinMénière’shasalso
beenfoundbysomeresearchersbutnotbyothers.
 
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Ocular Vestibular-Evoked Myogenic Potential
(oVEMP)
Iwasaki, S., Smulders, Y., Burgess, A., 
McGarvie, L., MacDougall, H., Halmagyi, G., 
et al. (2008). Ocular Vestibular Evoked Myogenic Potentials in 
Response to Bone-Conducted Vibration of the Midline Forehead at Fz. 
Audiology & Neurotology, 13, 396-404.
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
Morerecently,thecervicalVEMPhasbeensupplementedby
theocularVEMP,discoveredbyRosengrenandcolleagues
aboutfiveyearsago.
TheoVEMPisanexcitatoryresponserecordedfromthe
musclesbelowtheeyecontralateraltothestimulatedotolith
organs,mostlikelyviathispathwayandresultsinawaveform
thatlookslikethis.
ResearchintotheaffectofMénière’sontheoVEMPresponse
hasbeenmuchmorelimited.

 
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Outline of the present study
 Bilateral measurements of both cVEMPs and oVEMPs
 All Ménière's participants had transtympanic electrocochleography in 
months prior to testing
 Use of the term “clinically-certain” is somewhat provocative, but is there 
to signify “AAOHNS definite Ménière's Disease plus
electrocochleographic indicators of endolymphatic hydrops”

Inthisstudy,wecarriedoutbilateralmeasurementsofboth
cVEMPsandoVEMPsincontrolparticipantsandinpatientswith
Ménière’sdisease.
UnlikemanyoftheotherstudiesImentioned,allofour
Ménière’sparticipantshadtranstympanicelectrocochleography
inmonthspriortotesting.
Theuseoftheterm“clinicallycertain”issomewhat
provocative,butistheretosignify“AAOHNSdefiniteMénière's
Diseasepluselectrocochleographicindicatorsofendolymphatic
hydrops”
 
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Transtympanic electrocochleography (ECochG)
 ECochG carried out on all Ménière's patients by J. Hornibrook at 
Christchurch Hospital (using Amplaid MK 15, Milan, Italy).
 Electrode configuration: Active electrode on promontory, ground 
electrode on forehead, reference electrode on ipsilateral earlobe. 
Transtympanic ECochG
 Air conduction click and tone 
burst stimuli delivered via supra-
aural headphone positioned on 
ring over the test ear.
 100 s alt. clicks (10/s, 90 dB HL)
 Response filtered 0.5 - 2.5 kHz
 256 averages/waveform
 0.5, 1, 2, 4 kHz tonebursts
(16 ms, 1 ms rise/fall, 90 dB HL 
except 4 kHz at 100 dB HL)
 Response filtered 0.5 - 3 kHz
 1024 averages/waveform

Theelectrocochleographicrecordingswereperformedat
ChristchurchHospitalusingapromontoryelectrodereferenced
totheipsilateralearlobe.
WeusedbothclicksandtoneburstsandI’lldescribethe
analysisofthesewaveformsinamoment.



 
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Participants
 Participants were divided into two groups:
 Control group of 22 participants (9 male, 13 female) with no 
known vestibular pathologies
 Mean age of 34 ± 13 years (range: 22 to 63 years)
 Patient group with “clinically certain” Ménière’s disease (14 male, 
4 female), with positive ECochG signs of endolymphatic hydrops
 Mean age of 60 ± 8 years (range: 52 to 77 years)
 Participants were excluded if they had conductive hearing loss or 
problems maintaining head or eye position.
 Study approved by the Health and Disability Upper Regional A Ethics 
Committee (ref: URA/08/04/030) and the University of Canterbury 
Human Ethics Committee (ref: HEC 2008/61 and HEC 2009/LR/05). 

Wehadtwogroupsofparticipants:
22inthecontrolgroupand18intheMénière’sgroup.You’ll
noticethattheagerangeofthetwogroupsdifferssomewhat–
thismaybeaproblem,giventhataseveralstudieshavefound
decreasingVEMPamplitudewithage[OchiandOhashi(2003),Welgampola
andColebatch(2001)andSu,Huang,andCheng(2004)].Inaddition,whilesome
studieshavefoundnoeffectofageonVEMPlatencies[Bastaetal.
(2005)andSuetal.(2004)],othershave[Lee,Cha,Jung,Park,&Yeo,(2008)].
Participantswereexcludediftheyhadconductivehearingloss
orproblemsmaintainingtheheadoreyepositionrequiredto
activatethemuscleswewererecordingfrom.And,ofcourse,
thestudywasfullyapprovedbytherelevantEthicscommittees.
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Ménière's 
participant
characteristics
Patient
Affected 
ear
AAOHNS
criteria
Ménière's 
stage
Gibson 
score
ECochG results
SP/AP 
click 
stimulus
Positive result for 
tone burst stimuli 
(> 33% = 
abnormal 
SP/AP 
ratio) (0.5 – 4 kHz)
P1 Left D 3 10 73% 1, 2, & 4 
P2 Left D 2 9 50% 1, 2, & 4 
P3 Right D 3 9 - 1, & 2 
P4 Left D 3 10 51% 1
P5 Left D 2 10 56% 0.5, 1, & 2 
P6 Right D 4 10 - 0.5, 1, 2, & 4 
P7 Right D 3 7 - 1, & 2 
P8 Left D 3 8 - 1, 2 
P9 Left D 3 10 61% 0.5, & 1
P10 Right D 4 7 - 0.5, l, & 2 
P11 Left D 3 10 80% 0, 5, 1, & 2 
P12 Right D 1 10 - 0.5, 1, & 2 
P14 Right D 1 8 53% 0.5, 1, & 2 
P15 Right D 1 10 - 0.5, 1, & 2 
P16 Left D 3 8 56% 2, & 4 
P17 Right D 3 10 - 0.5, 1, & 4 
P18 Right D 1 10 - 0.5, l, & 2 
 Tone-burst ECochG results 
judged by Gibson’s (1992) 
normative data shown below.
Tone burst 
Frequency
Hearing level 
dB HL
Abnormal if
SP >
.5 kHz (75 dB HL)
Under 25 -2 V
20 – 35 -2 V
40 – 55 -2 V
60 – 75 -1 V
1 kHz (90 dB HL)
Under 25 -6 V
20 – 35 -6 V
40 – 55 -6 V
60 – 75 -3 V
2 kHz (100 dB HL)
Under 25 -9 V
20 – 35 -7 V
40 – 55 -5 V
60 - 75 -5 V
4 kHz (75 dB HL)
Under 25 -9 V
20 – 35 -5 V
40 – 55 -5 V
60 – 75 -5 V

TheMénière’spatientsinourstudywereroughlysplit50:50
right:leftintermsoftheearthatwasaffected.Allhad“Definite
Ménière’sDisease”accordingtotheAAOHNScriteria.

ThepatientshadtheirhearingcheckonthedayoftheVEMP
test,andwehadarangeofstagesofMénière’sfromstage1
throughtoStage4.

ThepatientshadGibsonscoresofbetween7and10andthe
patientsalltestedpositiveforhydropsintheirECochGresults,
accordingtoBillGibson’s1992criteria,shownhere.
 
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Data acquisition
 Custom-written evoked potential averaging and analysis software.

TorecordtheVEMPresponseswedevelopedourown
measurementsystemthatwascapableofrecordingfromboth
theleftandrightocularmusclesandneckmuscles
simultaneously.Inpractice,however,wefounditbettertohave
theparticipantsfocusontensingthesemusclesseparately.



 
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Data acquisition
 Custom-written evoked potential averaging and analysis software.
 cVEMP recordings:
 Active electrode on middle of SCM body, indifferent on upper 
sternum, ground on forehead.
 oVEMP recordings:
 Active electrode on orbital margin below eye, indifferent on cheek, 
ground on forehead.
 Electrical signals band pass filtered between 10 – 2000 Hz and 
amplified (gain 3000x) using a CED 1902 bio-amplifier (Cambridge 
Electronic Design, Cambridge, UK), and digitized by a NI USB-6215 
DAQ card (National Instruments, TX, USA). 

WeusedstandardelectrodeplacementsforthecVEMPandthe
oVEMP.

Detailsofthefilteringandamplificationareshownhere.



 
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Measurement
 VEMP response amplitude is dependent on EMG level during testing 
(Zhou & Cox, 2004; Akin, Murnane, Panus, Caruthers, Wilkinson, & Proffitt, 2004).
 EMG levels recorded to file during testing. Visual feedback regarding 
EMG level from target muscle presented to subject via LED indicators.
 Simultaneous measurement of 
VEMPs from multiple locations 
and using multiple interleaved 
stimuli
 e.g. VEMP thresholds were 
determined from waveforms 
evoked by stimuli at up to six 
different sound levels, 
reducing chance of EMG 
fluctuation during recording.
Interleaved oVEMPs at 
multiple sound levels
114 dB 109 dB 104 dB 99 dB
4 ms 500 Hz tone-bursts
1 ms rise-fall time. 10/second
Threshold not found, so present at 94 dB SPL, 89 dB SPL etc.
114 dB SPL
109 dB SPL
104 dB SPL
99 dB SPL
10 ms
2 μV

Beingamyogenicresponse,it’svitaltomaintainaconsistent
levelofmuscletonethroughouttesting.WeusedanLED
feedbacksystemtoindicatetotheparticipantwhentheyhad
contractedtheirmusclessufficiently.
Whenhuntingforthresholdsweinterleavedmultiplesound
levelstoensuretheywereallrecordedunderthesame
conditions.Ourstimuliwere4millisecond500Hztonebursts
presentedatarateof10persecond.
WealsomeasuredtheEMGcontinuouslyduringtherecordings
andnormalizedtheamplitudesofthewaveformsbytheEMG
level.
 
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 One independent variable:  Group, with 4 levels, including
 Control, left ear
 Control, right ear 
 Ménière’s, affected ear 
 Ménière’s, unaffected ear
 Seven dependent variables:  
 cVEMP:  Threshold, and P1N1 and N1P2 peak-to-peak amplitudes
 oVEMP: Threshold, and N1P1, P1N2 and N2P2 peak-to-peak amplitudes
 A series of Kruskal-Wallis one-way ANOVAs on Ranks, followed up with 
post-hoc tests with Dunn’s method if a significant group effect was 
detected.
 Significance level set at 0.05
Note:
Statistical analysis

Inouranalysis,welookedatthewaveformsevokedbysound
presentedtotheleftandrightearsofthecontrolparticipants,
andtotheaffectedandunaffectedearsoftheMénière’s
participants.
WemeasuredtheVEMPthresholdsandanumberofpeak
amplitudesandlatencies,andperformedstatisticalanalysison
theresultingdata.



 
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Refresher:
Box & whisker plots
median
outlier
75th percentile
25th percentile
90th percentile
10th percentile
Significantly different at 0.05*

Justaquickrefresherforthoseofyouwhohaven’tseenbox&
whiskerplotsinawhile.Theygivemuchmoreinformationthan
simplemeansandstandarddeviations.
Themedianisthelineatthecentreofthebox,withthevarious
percentilesgivingthespreadofdataasshown.
Inthefollowingplots,thesignificantdifferencesareindicated
withanasterisk.



 
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 No significant difference between Ménière’s ears and controls.
Results:
cVEMP threshold
Control, left ear Control, right ear Ménière’s, affected ear Ménière’s, non-affected ear
cVEMP threshold(dBSPL)
Ménière's
affectedear
Ménière's
unaffectedear
Control
Left
Control
Right
n=17 n=18n=22 n=18
No significant group effect 
(H = 4.513, df =3, p = 0.211)

Firstly,wefoundnosignificantdifferenceinthethresholdofthe
cervicalVEMPsbetweenournormalparticipantsandour
Ménière’sparticipants,orbetweentheearsoftheMénière’s
participants.



 
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 oVEMP threshold significantly elevated in affected ears of Ménière’s 
participants compared to their unaffected ears.
Results:
oVEMP threshold
Control, left ear Control, right ear Ménière’s, affected ear Ménière’s, non-affected ear
oVEMP threshold(dBSPL)
Ménière's
affectedear
Ménière's
unaffectedear
Control
Left
Control
Right
n=14 n=13n=21 n=21
Significant group effect
(H = 11.1, df =3, p = 0.011)
However, Ménière’s 
oVEMP thresholds not 
significantly different 
from control subjects

FortheoVEMPs,theMénière’sparticipantsdidshowa
differenceinthresholdbetweentheiraffectedandunaffected
ears,buttheyweren’tsignificantlydifferentfromtheresultsof
thecontrolparticipants.



 
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 Each peak-to-peak amplitude measure presented here was divided by 
the mean RMS amplitude of the EMG level during that recording.
 μV pp / μV RMS = “normalised microvolts (nμV)”
 Difference in VEMP response amplitudes measured on left and right 
sides of control participants made it necessary to analyse each side 
separately.
Results:
Measures of peak-to-peak amplitude

AsImentionedearlier,thepeaktopeakamplitudesI’mabout
toshowyouareallnormalizedbytheEMGinthatmuscleatthe
timeofrecording.
Wedidrunintoacomplicationthatourcontrolsubjects
showedquitedifferentpeakamplitudesbetweentheirright
andleftsides,whichwasveryinteresting.Thedifferences
weren’tstatisticallysignificant,buttheywereenoughtomake
usanalyzethemseparately.


 
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 Significant reduction in cVEMP P1-N1 amplitude for affected Ménière’s 
ears compared to right ear of the control group
Results:
cVEMP P1-N1 amplitude
N1
P1
Control, left ear Control, right ear Ménière’s, affected ear Ménière’s, non-affected ear
cVEMP P1N1amplitude
Ménière's
affectedear
Ménière's
unaffectedear
Control
Left
Control
Right
n=12 n=15n=18 n=15
Significant group effect
(H = 14.092, df =3, p = 0.003)

LookingatthecervicalVEMPsfirst,wefoundthatthattheP1N1
amplitudewassignificantlyreducedinMénière’ssubjects
comparedtotherightearofthecontrols…



 
Slide18
Results:
cVEMP N1-P2 amplitude
 Significant reduction in cVEMP N1-P2 amplitude for affected Ménière’s 
ears compared to right ear of the control group
N1
P2
Control, left ear Control, right ear Ménière’s, affected ear Ménière’s, non-affected ear
cVEMP N1P2amplitude
Ménière's
affectedear
Ménière's
unaffectedear
Control
Left
Control
Right
n=12 n=15n=18 n=15
Significant group effect
(H = 10.346, df =3, p = 0.016)

…aswasthenextpeakalong–theN1P2peak.Noneofthe
otherpeaksforthecVEMPshowedsignificantdifferences.



 
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Results:
oVEMP N2-P2 amplitude
 Significant reduction in oVEMP N2-P2 amplitude for affected Ménière’s 
ears compared to left ear of the control group
Control, left ear Control, right ear Ménière’s, affected ear Ménière’s, non-affected ear
P2
N2
oVEMP N2P2amplitude
Ménière's
affectedear
Ménière's
unaffectedear
Control
Left
Control
Right
n=8 n=10n=15 n=12
Significant group effect
(H = 11.549, df =3, p = 0.009)

FortheoVEMPs,theonlypeakthatshowedasignificant
differencewastheN2P2peak,shownhere,whichwas
significantlysmallerthanthoseevokedbytheleftearofthe
controlsubjects.



 
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Results summary:
Amplitude measures
 The following peak-to-peak amplitudes were significantly reduced in the 
Ménière’s ears compared to control ears (either right or left):
 cVEMP: P1N1 and N1P2
 oVEMP: N2P2
N2P2
P1N1 N1P2

So,thosepeaksthatshoweddifferencesaresummarizedhere.
Nowlet’stakealookatthepeaklatencies.



 
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cVEMP N1latency
Ménière's
affectedear
Ménière's
unaffectedear
Control
Left
Control
Right
n=11 n=15n=19 n=17
Results:
cVEMP N1 latency
 Latency of cVEMP N1 peak of affected Ménière’s ear significantly 
prolonged compared to both right and left ears of control group
N1
Control, left ear Control, right ear Ménière’s, affected ear Ménière’s, non-affected ear
Significant group effect
(H = 9.09, df =3, p = 0.028)

ForthecVEMPs,theonlypeaklatencywhichwassignificantly
differentbetweencontrolsandMénière’swastheN1peak,
shownhere.Thiswasdelayedbyabout5mscomparedtoboth
earsofthecontrolparticipants.



 
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oVEMP P2latency
Ménière's
affectedear
Ménière's
unaffectedear
Control
Left
Control
Right
n=8 n=11n=17 n=15
Results:
oVEMP latencies
 No statistically-significant difference in any of the oVEMP latencies 
among groups.
P2
Control, left ear Control, right ear Ménière’s, affected ear Ménière’s, non-affected ear
No significant group effect
(H = 10.53, df = 3, p = 0.015)

NoneoftheoVEMPpeaksshowedanylatencydifferences
betweenthecontrolsandMénière’sparticipants.Theclosest
wastheP2,whichwasdelayedbutnotsignificantly.



 
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Results:
Questionnaire – ease of each procedure
oVEMP significantly easier than cVEMP (p = 0.001)
oVEMP
cVEMP

ForthoseofyouwhohavehadtheirVEMPsmeasured,you’ll
knowthatitcanbequiteuncomfortableandrequiresalotof
effort,particularlyforelderlyparticipants.

WehadourparticipantsactivatetheirSCMmusclesforthe
cVEMPbyturningtheirheadandliftingitfromasupine
position,which,notsurprisingly,theyfoundquitedifficult.

TheoVEMP,ontheotherhand,requiredthemtolookupwards
andtowardthemidline.Ourparticipantsfoundthissignificantly
easier.
 
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Summary
 Threshold measures:
 No significant difference between VEMP thresholds of Ménière’s patients 
and controls participants (either cVEMP or oVEMP)
 Amplitude measures:
 P1N1 and N1P2 of cVEMP and N2P2 of oVEMP significantly reduced in 
affected ears of Ménière’s patients 
 Latency measures:
 cVEMP N1 peak latency significantly prolonged in affected ears of 
Ménière’s patients 
 Ease of procedure:
 oVEMP significantly easier than cVEMP, and preferred by 67% of 
participants
 Large overlap between results of Ménière’s patients and controls limits 
ability to reliably distinguish them on the basis of VEMP results alone.

Tosumup…


 
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Thanks to our participants, and to 
Assoc. Prof. Owen Murnane
for valuable comments.
Thank you!

Thanksverymuch.
